Sarasin NAD+ Longevity Pen

Cellular energy, mitochondrial function and healthy ageing. From within.

Beneath every visible sign of skin ageing there is a cellular story. Collagen breaks down faster than it is rebuilt. Mitochondria produce less energy per cell. DNA repair slows. These are not simply the inevitable consequences of time. They are the downstream effects of a specific molecular decline that ageing biology has identified with growing confidence: the progressive fall in NAD+, or nicotinamide adenine dinucleotide, one of the body’s most important and most studied coenzymes.

NAD+ does not work from the skin surface. It operates at the level where ageing actually begins: in the mitochondria where cellular energy is produced, in the nucleus where DNA damage is detected and repaired, and within the longevity pathways that determine how well and how long cells function over a lifetime. Human tissue studies have confirmed that NAD+ declines measurably with age, and that this decline correlates with the hallmarks of cellular ageing including mitochondrial dysfunction, oxidative stress and impaired DNA repair. (Massudi et al., 2012; Covarrubias et al., 2021)

The NAD+ Longevity Pen was selected within the Sarasin 360° SkinLongevity philosophy because it addresses what topical skincare cannot: the molecular substrate from which healthy ageing, including healthy skin ageing, proceeds. Sarasin NAD_ Longevity Pen (1)

Why this pen is different:

• Subcutaneous delivery introduces NAD+ directly into tissue, bypassing gastrointestinal degradation
• Precise microdosing via a clinical pen mechanism for controlled, consistent administration
• Integrates into a daily routine in under one minute, without an IV clinic appointment
• Refrigerated dispatch, sterile production standards, clear usage protocol included
• Claims grounded in human research — with honest disclosure of where evidence gaps remain Sarasin NAD_ Longevity Pen (1)

HOW TO USE?

How do you use the NAD+ Longevity Pen?

The pen is designed for subcutaneous self-administration according to the dosing protocol included with your order. Read the complete instructions before first use.

• Choose a clean injection site each time, rotating locations as guided in the protocol
• Use a new sterile needle for every single administration — never reuse needles
• Administer once daily, or according to the schedule provided — do not exceed the recommended dose
• Store cartridges refrigerated, protected from light and heat, including during travel
• Do not share the pen or needles with anyone
• Consult the Sarasin team or your physician before first use if you take medication or have existing health conditions

Seek medical advice before use during pregnancy or breastfeeding, with an active or prior cancer diagnosis, liver or kidney disease, serious chronic illness, or use of anticoagulants or systemic medication.

If you experience localised redness, persistent headache, nausea, palpitations or unusual restlessness, stop use and consult a physician. Seek urgent attention for serious symptoms.

This product is not a replacement for sleep, nutrition, physical activity or medical care. Individual responses vary and results cannot be guaranteed. Sarasin NAD_ Longevity Pen (1)

ABOUT THE FORMULA

What NAD+ is, why it declines, and why delivery route matters.

NAD+ is a coenzyme present in every cell and involved in hundreds of metabolic reactions. It carries electrons in the mitochondrial processes that convert nutrients into ATP, the form of energy cells run on. It is also the primary substrate for two critical enzyme families. Sirtuins (SIRT1 through SIRT7) are NAD+-dependent enzymes that regulate gene expression, mitochondrial biogenesis, metabolic adaptation and stress response pathways that determine cellular resilience over time. PARP enzymes use NAD+ to detect and repair DNA strand breaks. When NAD+ falls, both systems lose their substrate and their effectiveness falls with them.

The subcutaneous delivery route is designed to introduce NAD+ directly into tissue beneath the skin, where it enters the interstitial fluid and is absorbed into systemic circulation. This bypasses the gastrointestinal system, which breaks down orally administered NAD+ into metabolite fragments before absorption. The same pharmacological principle underpins insulin and many medical biologics: subcutaneous delivery is used specifically for compounds that are degraded by the gut. The clinical extent of the bioavailability advantage of subcutaneous NAD+ over oral supplementation in humans has not yet been established in direct comparative trials, and we state this clearly below.

Within the Sarasin 360° SkinLongevity method, the NAD+ Longevity Pen operates at the cellular level: alongside clinical treatments, topical actives and nutritional support, it addresses the molecular substrate that defines how cells function and age. It is the component of the system designed to work from the inside of the cell outward. Sarasin NAD_ Longevity Pen (1)

SCIENCE SAYS

Honest about what the evidence shows — and where the gaps are.

NAD+ is one of the most actively researched molecules in ageing biology. The quality of that evidence, however, varies by question. Understanding what it actually supports — and where it does not yet reach — is the foundation of every claim on this page. Sarasin NAD_ Longevity Pen (1)

What is established in human research

The age-associated decline of NAD+ in human tissue is well established. Massudi and colleagues (2012) measured NAD+ across age groups in human tissue and found a significant decrease alongside rising oxidative stress markers. Covarrubias and colleagues (2021) reviewed human and animal data in Nature Reviews Molecular Cell Biology and identified NAD+ depletion as a driver of multiple hallmarks of ageing. These are findings grounded in human biology.

Human clinical trials with NAD+ precursors NMN and NR have demonstrated that supplementation raises NAD+ metabolite concentrations in blood and skeletal muscle. Elhassan et al. (2019) showed NR raised NAD+ in blood and muscle in healthy older adults with anti-inflammatory transcriptomic changes. Yoshino et al. (2021) demonstrated that NMN improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes. Martens et al. (2018) confirmed NR was well tolerated and elevated NAD+ in healthy middle-aged and older adults. Intravenous NAD+ has also been studied directly: Grant et al. (2019) confirmed IV administration significantly raised plasma NAD+ metabolite levels in human subjects. Sarasin NAD_ Longevity Pen (1)

Distinguishing levels of evidence: human, animal and laboratory

In vitro studies have established with high confidence how NAD+ supports mitochondrial function, sirtuin activation and DNA repair. They tell us the biology but cannot confirm clinical benefit in living people. Animal studies, primarily in mice, show that raising NAD+ can extend healthy lifespan and improve metabolic function — compelling findings that have driven the human research agenda, but not directly transferable to human outcomes. Human clinical trials are the highest level of evidence. The human database is growing but remains smaller and more heterogeneous than the animal literature. The most consistent human finding is that supplementation raises NAD+ metabolite levels. Which specific clinical benefits follow in healthy adults, at which dose, and over what timescale, are still being established. All claims on this page are grounded in what human evidence supports. Sarasin NAD_ Longevity Pen (1)

Subcutaneous versus intravenous versus oral: the honest picture

No published clinical trial has directly compared the absorption, bioavailability and clinical outcomes of subcutaneous NAD+ administration against IV NAD+ or oral precursors in the same human subjects. This direct comparative evidence does not yet exist, and we state this without qualification.

What the available evidence shows is this: IV NAD+ raises plasma NAD+ metabolites significantly and rapidly in humans (Grant et al., 2019). Oral NAD+ and precursors are processed by the gut before systemic absorption, with much of the administered compound converted into metabolite fragments en route. Subcutaneous delivery bypasses this gastrointestinal conversion — the pharmacological rationale is sound and the route is established medical practice for many injectables. Whether this translates into meaningfully superior outcomes versus IV or well-dosed oral precursors in humans is a question that published comparative trials have not yet answered. We do not claim superiority against IV administration on the basis of evidence that does not exist. Sarasin NAD_ Longevity Pen (1)

NAD+ directly versus precursors: NMN and NR

NAD+ precursors such as NMN and NR are not NAD+ itself. They are molecules the body converts into NAD+ through enzymatic steps inside the cell. Most published human clinical trial evidence on raising NAD+ through supplementation involves these precursors, not direct NAD+ administration. The Longevity Pen delivers NAD+ as the complete molecule. When taken orally, NAD+ is largely broken down in the gut before absorption; subcutaneous delivery introduces the complete molecule directly into tissue, bypassing this conversion. Whether the cell uses directly delivered NAD+ differently from precursor-derived NAD+ is an active area of research. Published head-to-head human data comparing direct NAD+ delivery with precursor supplementation remains limited, and this is stated clearly. The biological rationale for direct delivery is well founded; the clinical superiority claim awaits the comparative trials that will test it. Sarasin NAD_ Longevity Pen (1)

WHAT’S INSIDE

Content: per protocol — see included product leaflet

Active compound and delivery system

NAD+ (Nicotinamide Adenine Dinucleotide): The primary active compound. A coenzyme central to mitochondrial ATP production, sirtuin enzyme activation and PARP-mediated DNA repair. Delivered here as the complete molecule via subcutaneous administration, bypassing the gastrointestinal degradation that reduces the systemic availability of orally ingested NAD+. Sarasin NAD_ Longevity Pen (1)

Sterile aqueous solution: NAD+ is formulated in a pharmaceutical-grade sterile carrier produced under controlled manufacturing conditions. Sterility is a non-negotiable requirement for any subcutaneously administered compound. Each cartridge is sealed to strict quality standards and must be stored refrigerated to preserve both sterility and molecular integrity throughout use.

Pen delivery mechanism: A precision pen system providing accurate, consistent microdosing with each administration. The fine-gauge needle is designed to minimise injection site discomfort and to allow reliable self-administration per the dosing protocol. A new sterile needle must be used at every single administration. The pen mechanism ensures the same controlled volume is delivered with each use, supporting consistent dosing across the protocol. Sarasin NAD_ Longevity Pen (1)

KEY STUDIES

The following peer-reviewed publications form the scientific basis for the claims on this page. Each is identified by evidence type.

Human tissue study:

Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012.

Human clinical trial — intravenous NAD+:

Grant R et al. Human plasma and urine NAD+ metabolome during intravenous NAD+. Frontiers in Aging Neuroscience. 2019. Sarasin NAD_ Longevity Pen (1)

Human clinical trial — NR in older adults:

Elhassan YS et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Reports. 2019.

Human clinical trial — NMN in prediabetic women:

Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.

Human clinical trial — NR in healthy adults:

Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018.

Comprehensive review — human and animal data:

Covarrubias AJ et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. Sarasin NAD_ Longevity Pen (1)

The claims on this page reflect the current state of published human research on NAD+ biology and supplementation. Where direct comparative clinical data between delivery routes is not yet available, this is stated explicitly. Sarasin Clinic is committed to scientific accuracy and transparent communication as the foundation of the 360° SkinLongevity approach.

This product is a wellness supplement and is not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before beginning any injectable supplementation programme. Sarasin NAD_ Longevity Pen (1)